Most Read Articles
15 Sep 2016
Tigecycline therapy produces favourable outcomes in severe Clostridium difficile infection (sCDI), says a study.
Roshini Claire Anthony, 22 May 2018

The combined use of piperacillin and tazobactam does not appear to be a suitable alternative to meropenem for patients with bloodstream infections caused by ceftriaxone-resistant Escherichia coli (E. coli) or Klebsiella pneumoniae (K. pneumoniae), according to results of the MERINO* trial.

Pearl Toh, 28 Dec 2017
The addition of low oxygen levels measured by pulse oximetry to the three signs delineated in the current diagnostic model for pneumonia in primary care setting derived by van Vugt, which include fever, tachycardia, and crackly breath sounds on auscultation, can add value to diagnostic precision and help general practitioners (GPs) differentiate pneumonia from less serious infections, a study suggests.
26 Sep 2017
Ceftazidime-avibactam appears to offer a reasonable alternative to colistin in the treatment of Klebsiella pneumoniae carbapenemase (KPC)-producing carbapenem-resistant Enterobacteriaceae (CRE) infections, according to a study.

Antiviral therapy improves surgery-free survival in UC patients

10 Apr 2018

Antiviral treatment for colonic cytomegalovirus (CMV) infection significantly improves short- and long-term surgery-free survival in patients with ulcerative colitis (UC), according to the results of a small-scale study.

Patients in treated and nontreated groups had similar demographic variables. Patients who received antiviral therapy had significantly improved surgery-free survival within 30 days and lasted 70 months (p<0.01).

On the other hand, both treated and nontreated groups showed similar rates of hospitalization, rehospitalization and mortality (p>0.05). Furthermore, there was no significant between-group difference in any of the clinical outcomes based on viremia status.

In total, 1,478 patients who had colon biopsy and were tested for CMV during 1990–2013 were identified from the Cleveland Clinic pathology database. Forty-one UC patients were selected after inclusion and exclusion, of whom 24 (58.5 percent) received treatment and 17 (41.5 percent) did not.

The authors compared 14 demographic data and four clinical outcomes (surgery-free survival, hospitalization, rehospitalization and mortality) between treated and nontreated patients. They also compared the same outcomes in patients who received treatment based on their viremia status.

“The frequency of CMV colitis in steroid-refractory inflammatory bowel disease has been reported to range from 15.8–34.0 percent. Infected patients are more likely to become hospitalized, have longer lengths of stay and higher mortality rates,” the authors said.

“Current data are limited to small scale studies and showed conflicting result regarding the role of antiviral therapy,” they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
15 Sep 2016
Tigecycline therapy produces favourable outcomes in severe Clostridium difficile infection (sCDI), says a study.
Roshini Claire Anthony, 22 May 2018

The combined use of piperacillin and tazobactam does not appear to be a suitable alternative to meropenem for patients with bloodstream infections caused by ceftriaxone-resistant Escherichia coli (E. coli) or Klebsiella pneumoniae (K. pneumoniae), according to results of the MERINO* trial.

Pearl Toh, 28 Dec 2017
The addition of low oxygen levels measured by pulse oximetry to the three signs delineated in the current diagnostic model for pneumonia in primary care setting derived by van Vugt, which include fever, tachycardia, and crackly breath sounds on auscultation, can add value to diagnostic precision and help general practitioners (GPs) differentiate pneumonia from less serious infections, a study suggests.
26 Sep 2017
Ceftazidime-avibactam appears to offer a reasonable alternative to colistin in the treatment of Klebsiella pneumoniae carbapenemase (KPC)-producing carbapenem-resistant Enterobacteriaceae (CRE) infections, according to a study.